logo
Book a meeting
MARAbio

Mar Abio

Biotechnology, 26 S Rio Grande St, Salt Lake City, Utah, 84101, United States, 1-10 Employees

marabio.com

  • LinkedIn

phone no Phone Number: +16*********

Who is MARABIO

We identify the risk of developing Maternal Autoantibody Related Autism (MARA), a subtype of autism that is estimated to represent approximately 20% of overall cases, through a new type o...

Read More

lock icon Get Full Access
map
  • 26 S Rio Grande St, Salt Lake City, Utah, 84101, United States Headquarters: 26 S Rio Grande St, Salt Lake City, Utah, 84101, United States
  • 2016 Date Founded: 2016
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2835 | NAICS Code: 325413 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from MARABIO

MARAbio Org Chart and Mapping

Employees
Michael Paul

Michael Paul

CEO, President, and Member Board of Directors

Marnin Kligfeld

Marnin Kligfeld

Chairman of Board

See Full Org Chart arrow
email-formate-icon
View Email Formats for MARAbio
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding MARAbio

Answer: MARAbio's headquarters are located at 26 S Rio Grande St, Salt Lake City, Utah, 84101, United States

Answer: MARAbio's phone number is +16*********

Answer: MARAbio's official website is https://marabio.com

Answer: MARAbio's revenue is $5 Million to $10 Million

Answer: MARAbio's SIC: 2835

Answer: MARAbio's NAICS: 325413

Answer: MARAbio has 1-10 employees

Answer: MARAbio is in Biotechnology

Answer: MARAbio contact info: Phone number: +16********* Website: https://marabio.com

Answer: We identify the risk of developing Maternal Autoantibody Related Autism (MARA), a subtype of autism that is estimated to represent approximately 20% of overall cases, through a new type of risk assessment test for prospective mothers prior to (but not during) pregnancy, and for mothers during the early postnatal period. Our goal is to provide families with options to materially reduce the occurrence or severity of MARA. Our precision technology uses a blood test in women to identify the presence of a distinct cluster of autoantibodies that lead to MARA, thereby enabling the earliest risk assessment for the development of autism in a child.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access